Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study.
J Clin Exp Hepatol
; 12(1): 61-67, 2022.
Article
em En
| MEDLINE
| ID: mdl-35068786
AACE, American Associaton of Clinical Endocrinologists; ADR, Adverse Drug Reaction; ALT, Alanine Transaminase; BMI, Body Mass Index; CDSCO, Central Drugs Standard Control Organisation; CT Scan, Computed Tomography Scan; DBP, Diastolic Blood Pressure; DCGI, Drug Controller General of India; FBS, Fasting Blood Sugar; GLP1Ra, Glucagon Like Peptide 1 Receptor agonist; HCV, Hepatitis - C Virus; HDL, High Density Lipoprotein; HbA1C, Glycated Hemoglobin; IHEC, Institutional Human Ethics Committee; LDL-C, Low Density Lipoprotein Cholesterol; LSM, Liver Stiffness Measurement; MRI, Magnetic Resonance Imaging; NAFLD, Nonalcoholic Fatty Liver Disease; NASH, Non-Alcoholic Steatohepatitis; NPV, Negative Predictive Value; Na2EDTA, Sodium Ethylenedinitrilotetraacetic acid; PPAR, Peroxisome Proliferator Activated Receptor; PPBS, Post Prandial Blood Sugar; SBP, Systolic Blood Pressure; SDB, Serum Direct Bilirubin; SGLT2i, Sodium Glucose Co-Transporter-2 Inhibitor; SGOT, Serum Glutamate Oxaloacetic Transaminase; SGPT, Serum Glutamate Pyruvic Transaminase; SPSS, Statistical Package for the Social Sciences; STB, Serum Total Bilirubin; T2DM, Type 2 Diabetes Mellitus; TC, Total Cholesterol; TG, Triglycerides; TZD, Thiazolidinediones; USG, Ultra Sonography; VLDL, Very Low Density Lipoprotein; diabetic dyslipidemia; fibrosis level; non-alcoholic fatty liver disease; saroglitazar; ultrasound
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article